Affiliations: [a] Sorbonne Université, Science Norms Democracy, UMR 8011, Paris, France
| [b] Programa de Bioética, Facultad Latinoamericana de Ciencias Sociales (FLACSO), Buenos Aires, Argentina
| [c]
National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
| [d] Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France
| [e] FrontLab, ICM, Paris, France
| [f] AP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer’s Disease (IM2A), Centre of Excellence of Neurodegenerative Disease (CoEN), National Reference Centre for Rare and Early Dementias, Department of Neurology, Paris, France
Correspondence:
[*]
Correspondence to: Dr. Timothy Daly, Faculty of Letters, Sorbonne Université, Paris 75005, France. E-mail: [email protected].
Abstract: Given the unknown therapeutic value of targeting Alzheimer’s disease pathology and the discovery of robust risk factors for dementia, non-pharmacological risk reduction (RR) is increasingly offered as an alternative to targeting Alzheimer’s disease pathology. While RR will surely be a useful tool to make public health gains, we propose solutions to three possible issues with over-reliance on multi-domain interventions to achieve RR: limited individual impact, an exclusive focus on later life, and overlooking social determinants of dementia. We argue in favor of a broader debate within the research community and greater society about how different therapeutic avenues should be explored.
Keywords: Alzheimer’s disease, dementia, health inequities, multidomain interventions, public health, risk reduction, social determinants of health
